Moteur de recherche d’entreprises européennes
Financement de l’UE (4 470 728 €) : Apprentissage automatique pour la conception intégrée d’enzymes et de bioprocédés multiparamétriques Hor 27/06/2025 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Apprentissage automatique pour la conception intégrée d’enzymes et de bioprocédés multiparamétriques
Currently, our world is facing several global challenges like climate change, water pollution, land erosion, resource depletion and unsustainable manufacturing. Biotechnology can provide many solutions to these problems. One example is the development of sustainable bioprocesses, which is at the heart of the EU’s green deal. Enzymes are nature’s catalysts at the core of such transformation since they can catalyse complex biocatalytic reactions. Biocatalysis has been slowly but gradually displacing traditional organic chemistry in several processes by virtue of its better efficacy, with the added value of being less wasteful as evidenced by the cornucopia of EPA Green Chemistry Awards conferred to enzymatic processes. Thanks to protein directed evolution (Nobel Prize 2018), enzyme function can be tailored to new-to-nature industrial conditions within bioreactors. However, there are still many challenges limiting bioprocess scalability, owing to a lack of deep understanding of enzyme function and of efficient strategies to overcome the complex multi-factorial optimisation problem of both enzymes and bioprocesses. To address this gap, also known as the valley of death (i.e., a large investment gap between fundamental and applied research), ELEGANCE will offer a unique educational program combining state-of-the-art experimental and computational approaches including data science and artificial intelligence to design better enzymes and bioprocesses faster. The main goal is to train a new generation of specialists with essential hard and soft skills for transforming biocatalysis into a data-driven discipline to accelerate bioprocess development, thereby anticipating potential challenges arising in the valley of death. ELEGANCE will focus on enzymes catalysing highly selective oxyfunctionalisation reactions, unattainable through existing chemical technology, with ecological and economic attractiveness to enable the transition to a circular bioeconomy in many industries.
| Astrazeneca AB | ? |
| Aarhus Universitet | 335 890 € |
| Acib GmbH | 605 086 € |
| Agencia Estatal Consejo Superior de Investigaciones Cientificas | 282 188 € |
| Ceske Vysoke Uceni Technicke V Praze | 280 023 € |
| Danmarks Tekniske Universitet | 671 780 € |
| Datahow Srl | 281 755 € |
| Freie Universitaet Berlin | 290 272 € |
| Masarykova Univerzita | 280 023 € |
| Peaccel | 314 669 € |
| Sveuciliste U Zagrebu Fakultet Kemijskog Inzenjerstva I Tehnologije | 259 812 € |
| Technische Universiteit Delft | 305 286 € |
| Universita Degli Studi Di Torino | 281 755 € |
| Universitat de Girona | 282 188 € |
https://cordis.europa.eu/project/id/101226960
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : AstraZeneca AB, Södertälje, Suède.
